Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

Keytruda to Reduce Death Risk by 31%

Merck
Merck, known as MSD outside the United States and Canada, announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherap...

Successful Trial for UroGen’s Cancer Drug

Former Novartis oncology chief Liz Barrett’s decision to jump ship to lead the biotech UroGen appears to have been vindicated after the company announced top-line results showing its lead drug could c...

Liver Cancer Drug of Bayer has Final NICE Recommendation

bayer
Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer. Stivarga (regorafenib) is reco...

Prophylactic Vaccines are Most Popular among Cancer Vaccines

Cancer vaccines are a type of immunotherapy used to either treat existing cancer or prevent the development of cancer. Cancer treatment vaccines, also called therapeutic vaccines, work to boost the...

GE Healthcare and VUMC to Develop New DIagnostic Tools for Cancer Treatment

New diagnostic tools will be developed by GE Healthcare and Vanderbilt University Medical Centre (VUMC) to help make cancer immunotherapies safer and more accurate. As part of a five-year partnersh...

Adaptive and Genentech to Develop Treatment of Cancers

Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to dev...

BioNTech and Sanofi to Co-develop Cancer Immunotherapy

French multinational pharmaceutical company Sanofi investing €80m in equity in BioNTech, which is claimed to be the Europe’s largest privately-held biopharmaceutical firm focused on the development of...

Takeda to Develop Novel CAR-T Products

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology. In the first deal, Takeda will collaborate with Mem...

Samumed’s Pancreatic Cancer Drug Granted ODD

Samumed, LLC announced that the U.S. Food and Drug Administration granted orphan drug designation (ODD) for SM08502 for the treatment of pancreatic cancer. A phase 1, open‐label, multicenter, dose es...

Jazz Pharmaceuticals and Codiak to R&D Cancer Treatment

Jazz Pharmaceuticals plc and Codiak BioSciences, Inc. announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of e...

AbbVie and Tizona to Develop Antibody for Cancer Treatment

AbbVie, a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc., a privately held immunotherapy company, announced on Jan. 3, 2019 that they have entered into a global, strate...

Almac Brings Online Second GMP Peptide Facility

Based in Edinburgh, Scotland, the facility manufactures neoantigen derived peptides for use in the production of patient specific, individualised cancer vaccines Almac Group has brought online a se...

Chinese Pharma Collaboraton for Cancer Drug Development

InventisBio announced that it has signed a "Collaboration Agreement" with Betta Pharma. Under this agreement, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong ...

First Patient Dosed in First-Line Treatment of Advanced Cancer

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced that the first patient has been dosed in a phase III clinical trial...

Xynomic Files 3 IND Applications to Test Abexinostat

Xynomic Pharma, a clinical stage US-China oncology drug development company, today announced that its Trials-in-Progress poster discussing the ongoing, potentially pivotal, phase 3 trial of abexinosta...

Vedanta Raised $27m to Investigate Microbiome-Derived Therapies

US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and food allergy. Investors include...